Canadian Cancer Trials Group Bulletins

General


Recent Publications

Zhu L, Tan X, Tu D. Testing the homogeneity of two survival functions against a mixture alternative based on censored data. Communications in Statistics - Simulation & Computation 39: 767-76, 2010.

http://www.informaworld.com/smpp/content~db=all?content=10.1080/03610911003637414&waited=0

-------------

Tan X, Takahara G, Tu D. Optimal two-stage design for the phase II cancer clinical trials with responses and early progression as co-primary endpoints. Statistics in Biopharmaceutical Research 2: 348-54, 2010.

http://pubs.amstat.org/doi/abs/10.1198/sbr.2009.08079

-------------

IND.165 -- Primary Results

Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer (ONLINE). J Clin Oncol 2010.

http://jco.ascopubs.org/cgi/content/abstract/JCO.2009.26.8771v1?cmpid=jco_pap_23August2010

-------------

OV.13 Primary Results
(An International Multi-Centre Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma)

Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RHM, van der Burg MEL, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GCE, Pecorelli S, and Reed NS, for the European Organization for Research and Treatment of Cancer -- Gynaecological Cancer Group and the Canadian Cancer Trials Group -- a Gynecologic Cancer Intergroup Collaboration. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. N Engl J Med 2010; 363:943-953.

http://www.nejm.org/doi/full/10.1056/NEJMoa0908806?query=TOC